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Chikungunya virus (CHIKV) is an important re-emerging human pathogen 17 
transmitted by mosquitoes. The virus causes an acute febrile illness, chikungunya fever, 18 
which is characterized by headache, rash and debilitating (poly)arthralgia that can reside 19 
for months to years after infection. Currently, effective antiviral therapies and vaccines are 20 
lacking. Due to the high morbidity and economic burden in the countries affected by 21 
CHIKV, there is a strong need for new strategies to inhibit CHIKV replication. The 22 
serotonergic drug, 5-nonyloxytryptamine (5-NT), was previously identified as a potential 23 
host-directed inhibitor for CHIKV infection. In this study, we determined the mechanism of 24 
action by which the serotonin receptor agonist 5-NT controls CHIKV infection. Using time-25 
of-addition and entry bypass assays we found that 5-NT predominantly inhibits CHIKV in 26 
the early phases of the replication cycle; at a step prior to RNA translation and genome 27 
replication. Intriguingly, however, no effect was seen during virus-cell binding, 28 
internalization, membrane fusion and gRNA release into the cell cytosol. Additionally, we 29 
show that the serotonin receptor antagonist MM also has antiviral properties towards 30 
CHIKV and specifically interferes with the cell entry process and/or membrane fusion. 31 
Taken together, pharmacological targeting of 5-HT receptors may represent a potent way 32 
to limit viral spread and disease severity. 33 
 34 
Importance 35 
The rapid spread of mosquito-borne viral diseases in humans puts a huge 36 
economic burden on developing countries. For many of these infections, including 37 
Chikungunya virus (CHIKV), there are no specific treatment possibilities to alleviate 38 
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disease symptoms. Understanding the virus:host interactions that are involved in the viral 39 
replication cycle is imperative for the rational design of therapeutic strategies. In this study, 40 
we discovered an antiviral compound and elucidated the mechanism of action and 41 
propose serotonergic drugs as potential host-directed antivirals for CHIKV.  42 
 43 
Introduction  44 
Chikungunya fever is an important re-emerging mosquito-borne human disease 45 
caused by Chikungunya virus (CHIKV). Over the past decade, the virus has continued to 46 
spread throughout the Americas and Asia thereby infecting millions of people (1). 47 
Chikungunya fever is characterized by fever, headache, rash, and myalgia. A potential 48 
long-lasting and debilitating feature of CHIKV infection is the onset of (poly)arthralgia 49 
and/or polyarthritis which can last months to years after infection (2, 3). Roughly 85% of 50 
all infected individuals develop chikungunya fever of which approximately 30-40% develop 51 
long lasting (poly)arthralgia/arthritis (1, 4). Consequently, CHIKV has a high morbidity and 52 
economic burden in the countries affected especially since there are no vaccines nor 53 
antiviral therapies available. 54 
Antiviral therapies against CHIKV should be designed with the aim to lower viral 55 
burden and/or to prevent the onset of chronic disease. There are two classes of antivirals: 56 
1) direct-acting drugs, which target the virus itself and 2) host-directed drugs, which target 57 
cellular factors important for the replication cycle of the virus (5–7). An advantage of direct-58 
acting antivirals is that these are more specific, however, viral resistance is often quickly 59 
obtained (8). Host-directed antivirals, on the other hand, are less specific and may cause 60 
more side-effects yet the development of viral resistance is greatly reduced (9). To identify 61 
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novel host-directed antivirals, it is imperative to understand the dynamic and temporal 62 
interactions of the virus with the host during infection.  63 
To initiate infection, CHIKV interacts with cellular receptors expressed at the 64 
plasma membrane. Among others, the cell adhesion molecule Mxra8 and N-sulfated 65 
heparan sulfate have been proposed as putative receptors for CHIKV, thereby facilitating 66 
virus internalization via clathrin-mediated endocytosis (6, 10). The acidic lumen of the 67 
early endosome subsequently triggers conformational changes in the E2 and E1 viral 68 
spike glycoproteins leading to E1-mediated membrane fusion (11, 12). Thereafter, the 69 
viral nucleocapsid is dissociated by an as yet ill-understood process and the positive-70 
sense RNA is translated to form the non-structural proteins of the virus. These non-71 
structural proteins interact with multiple cellular factors to facilitate 1) RNA replication, 2) 72 
translation of structural proteins from the viral subgenomic mRNA, and 3) production of 73 
new genomic RNA. The structural proteins E1 and a precursor E2 are translocated to the 74 
ER where heterodimerization of E1/E2 occurs. Maturation of the E1/E2 viral spike complex 75 
occurs via transit through the cellular secretory pathway. Progeny genomic RNA interacts 76 
with newly produced viral capsid proteins to form a nucleocapsid which is transported to 77 
the plasma membrane where virion assembly and budding occurs (13, 14). 78 
Serotonin (5-hydroxytryptamine; 5-HT) receptors are expressed at the plasma 79 
membrane and known to facilitate or alter the infectivity of different classes of viruses (15–80 
17). Most of the 5-HT receptors are G-protein coupled receptors and regulate important 81 
physiological functions and signaling pathways, including the cycling adenosine 82 
monophosphate (cAMP), calcium and phosphatidylinositol pathways (18). There are 83 
multiple subtypes of 5-HT receptors and these are divided into 7 families (19). The 5-HT2 84 
receptor family has been described to facilitate cell entry of JC polyomavirus (20) and 5-85 
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HT1 is suggested to be involved in HIV-1 replication (21). Furthermore, the infectivity of 86 
multiple RNA viruses were found to be controlled by 5-HT receptor agonists and 87 
antagonists (9, 22–24). Indeed, reovirus and CHIKV infectivity was found reduced in the 88 
presence of the 5-HT receptor agonist 5-nonyloxytryptamine (5-NT), which is described 89 
as a specific 5-HT1B/5-HT1D receptor agonist though it has also low level affinity to other 90 
5-HT receptor families (24, 25). 5-NT was shown to interfere with reovirus intracellular 91 
transport and disassembly kinetics during cell entry (24). Opposed to the agonist, the 5-92 
HT receptor antagonist methiothepin mesylate (MM) increased reovirus infectivity. 93 
However, it is yet unclear whether the mechanism of action of 5-HT receptor stimulation 94 
with this 5-HT receptor agonist and antagonist is the same for CHIKV.  95 
In this study, we confirmed the antiviral properties of 5-NT and unraveled the mode 96 
of action in CHIKV infection. Also, and in contrast to that observed for reovirus, we found 97 
an antiviral effect of the serotonin receptor antagonist MM towards CHIKV. We show that 98 
the serotonergic drugs 5-NT and MM target distinct steps during CHIKV cell entry and 99 
conclude that targeting 5-HT receptors may be a novel strategy to alleviate CHIKV 100 
disease.  101 
 102 
Results 103 
5-NT strongly inhibits CHIKV infection and virus particle production in U-2 OS 104 
cells 105 
The effect of 5-NT on CHIKV infectivity was analyzed in human bone osteosarcoma 106 
epithelial U-2 OS cells as epithelial cells are natural targets during human CHIKV infection 107 
(26, 27). Also, these cells were used by Mainou and co-workers who previously identified 108 
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5-NT as an inhibitor of CHIKV and reovirus infection (24). First, the mRNA expression 109 
levels of 10 distinct 5-HT receptor subtypes were determined in U-2 OS cells. We 110 
confirmed expression of 8 distinct 5-HT receptor subtypes including the 5-HT1B and 5-111 
HT1D receptor to which 5-NT binds with high affinity (Fig 1A). Next, we assessed the 112 
cellular cytotoxicity of 5-NT in U-2 OS cells by MTT assay and revealed no significant 113 
cytotoxicity up to a concentration of 5µM 5-NT (Fig 1B). The highest dose in our infectivity 114 
experiments was therefore set at 5µM 5-NT. 5-NT was dissolved in DMSO and the final 115 
DMSO concentration was below 1% in all experiments. Then, we analyzed CHIKV-LR 116 
infectivity and infectious virus particle production in U-2 OS cells in the presence of 117 
increasing concentrations of 5-NT. Cells were pretreated with increasing doses of 5-NT 118 
or NH4Cl, a lysosomotropic agent known to neutralize the endosomal pH and thereby 119 
inhibiting the membrane fusion activity of CHIKV, for 1 h and infected with CHIKV-LR 120 
5’GFP at MOI 5. At 20 hpi, cells and supernatants were collected and analyzed for GFP 121 
expression by flow cytometry and the production of infectious virus particles by plaque 122 
assay, respectively. A clear dose-dependent reduction in the number of CHIKV-infected 123 
cells was observed (Fig 1C). Importantly, the vehicle control DMSO had no significant 124 
effect on the number of infected cells (Fig 1C). CHIKV infection was reduced from 50.8% 125 
± 3.0% to 9.2% ± 2.9% (corresponding to 82% ± 6.4% reduction) in presence of 5µM 5-126 
NT (Fig 1C). The 50% effective concentration (EC50) i.e. the concentration in which 50% 127 
reduction is achieved was found to be 2.8µM 5-NT (95% CL, 2.2-3.6 µM). In line with 128 
these results, we also observed a reduction in infectious virus particle production. At a 129 
concentration of 5µM 5-NT, infectious virus particle production was reduced with >1 log10 130 
(94% ± 4.4%) when compared to the vehicle control (Fig 1D). These results correspond 131 
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to the findings of Mainou and colleagues and confirm that 5-NT interferes with productive 132 
CHIKV infection (24).  133 
 134 
5-NT inhibits CHIKV infection in first stages of the replication cycle  135 
To unravel the mode of action of 5-NT in controlling CHIKV infection, we first 136 
investigated the potential virucidal activity of 5-NT on CHIKV. To this end, CHIKV-LR 137 
5’GFP virions were incubated with 5µM 5-NT for 1.5 h after which viral infectivity was 138 
measured by a plaque assay. Within the plaque assay the final end concentration of 5-NT 139 
was below 0.5µM as the highest dilution used was 1:10. Incubation with 5-NT did not 140 
reduce viral infectivity, demonstrating that 5-NT does not have a direct negative effect on 141 
the infectivity of CHIKV particles (Fig 2A). Thereafter, a time-of-addition experiment was 142 
performed to delineate where 5-NT acts in the replicative cycle. In these experiments, it 143 
is important to analyze the results within one round of replication and therefore we first 144 
performed a growth curve analysis on U-2 OS cells. Figure 2B shows that initial GFP 145 
fluorescence is detected at 6 hpi (light grey bars, Fig 2B) and robust infectious virus 146 
particle production is seen at 8 hpi (dark grey bars, Fig 2B). To increase the sensitivity of 147 
the read-out we decided to analyze the effect at 10 hpi which still represents one round of 148 
replication. In the time-of-addition assay, cells were treated with 5-NT or DMSO for 1 h 149 
prior to infection (pre), during the adsorption of the virus (during), 1.5 h after adsorption 150 
(post), or a combination of treatments (Fig 2C). The results were normalized to the DMSO 151 
vehicle control. The strongest inhibition of infection was observed when 5-NT was present 152 
prior to and during virus adsorption (96% ± 1.2% reduction), which is comparable to 153 
treatment during the full course of infection (95% ± 2.6%) (Fig 2D). There is also a clear 154 
reduction in viral infectivity when 5-NT was present prior to (71% ± 2.6%) or during (75% 155 
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± 1.2%) virus adsorption yet this is significantly lower when compared to complete 156 
treatment conditions. Only 29% ± 8.7% reduction in infection is seen when 5-NT is added 157 
after adsorption of the virus. Collectively, these data suggest that 5-NT predominantly 158 
inhibits CHIKV infection during the early stages of the viral replication cycle.  159 
  160 
Cell entry bypass of the viral genome circumvents 5-NT antiviral activity 161 
To confirm that the serotonin receptor agonist predominantly inhibits CHIKV early 162 
in infection, we next evaluated the effect of 5-NT in an infection by-pass experiment. To 163 
this end, cells pretreated with 5-NT or vehicle control DMSO were harvested and 164 
transfected with in vitro transcribed viral RNA by electroporation. Following 165 
electroporation, cells were incubated for 12 h in presence of cell culture medium 166 
complemented with the compounds. Alternatively, cells were only exposed to 5-NT or 167 
DMSO after electroporation. A latter harvesting time-point was chosen to allow for cell 168 
recovery due to the electroporation procedure. At these conditions, the infectious virus 169 
particle production was 6.6 ± 0.6 Log PFU/mL in DMSO control cells. A comparable virus 170 
titer, 6.7 ± 0.2 Log PFU/mL was detected when cells were solely pretreated with 5-NT. 171 
Also, no major effect in infectious virus particle production were seen in cells treated with 172 
5-NT at post-electroporation (6.5 ± 0.6 Log PFU/mL) and pre- and post-electroporation 173 
(6.3 ± 0.8 Log PFU/mL) conditions (Fig 3A). An inhibitory effect was, however, seen in the 174 
percentage of infected cells (Fig 3B). It is important to note, however, that this result might 175 
be slightly biased since we detect GFP fluorescence at 6 hpi during normal infection 176 
conditions and thus at 12 hpi we may pick-up two rounds of replication. The observed 177 
reduction in the number of infected cells may therefore be due to an inhibition in re-178 
infection. Notably, in this experimental set-up, we observed high viral titers, which is 179 
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indicative for a high transfection efficiency. To validate if 5-NT still exhibits potent antiviral 180 
activity at these conditions, we next determined the inhibitory capacity of 5-NT following 181 
infection at high MOI. As a control we also determined the viral titer at 4 hpi to ensure that 182 
we properly removed the high concentration of virus inoculum and revealed a residual titer 183 
of 2.9 Log confirming that we predominantly detect progeny virions at 10 hpi. Under 184 
standard infection conditions at MOI 60, a viral titer of 6.0 ± 0.1 Log PFU was observed at 185 
10 hpi (Fig 3C). Importantly, at these conditions, we still observe a robust antiviral activity 186 
of 5-NT. The viral titer was 5.1 ± 0.3 Log PFU, which corresponds to 0.9 Log reduction in 187 
infectivity in one round of replication (Fig 3C). Altogether, these data confirms that 5-NT 188 
predominantly interferes with the early steps of the CHIKV replication cycle, hence before 189 
the viral RNA is released in the cell cytosol.  190 
 191 
5-NT does not affect CHIKV cell binding  192 
First, we assessed whether the binding capacity and internalization properties of 193 
CHIKV in U-2 OS cells is affected in presence of 5-NT. Initially, we determined the 194 
interaction of CHIKV with the host cell surface by use of 35S-labeled CHIKV particles. To 195 
mimic the pre- and during adsorption conditions of the time-of-addition experiments, cells 196 
were pretreated with 5-NT or vehicle control DMSO for 1 h after which 1x105 dpm 35S-197 
labeled virus (equivalent to ~1.0x109 genome equivalent copies (GECs) and 2.6x108 PFU) 198 
was added in cold medium in presence and absence of 5-NT. Incubation was continued 199 
for 3 h at 4⁰C to maximize virus-cell binding. At these conditions, internalization of virus 200 
particles is inhibited (28). Thereafter, cells were washed thoroughly to remove unbound 201 
virions and harvested by trypsinization. Radioactivity was counted in the total volume by 202 
scintillation counting as a measure of virus-cell binding. We measured on average 203 
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1.27x104 and 1.33x104 dpm in the absence or presence of 5-NT, respectively (Fig 4A). 204 
This indicates that 5-NT does not interfere with virus-cell binding of 35S-labeled CHIKV.  205 
To verify this finding, we next quantified the number of bound and/or internalized 206 
GECs by real-time quantitative reverse-transcription PCR (RT-qPCR). To this end, 5-NT 207 
or control-treated cells were exposed to CHIKV (~1.5x108 GECs, corresponding to MOI 5) 208 
at 37⁰C for 1.5 h to allow virus-cell binding and subsequent internalization. We used a 209 
shorter incubation time to limit the chance of detecting progeny viral RNA. Furthermore, 210 
RT-qPCR is more sensitive compared to the above approach. After 1.5 h, the cells were 211 
extensively washed to remove unbound particles and directly lysed in the cell culture plate 212 
for RNA isolation and subsequent RT-qPCR analysis. In agreement with the data shown 213 
in Fig 4A, we found no difference in total GECs bound and/or internalized between 214 
samples treated with 5-NT or vehicle control DMSO (Fig 4B). Collectively, these results 215 
indicate that 5-NT does not interfere with CHIKV cell binding at the cell surface. 216 
 217 
Virus internalization and membrane hemifusion is not affected upon 5-NT 218 
treatment  219 
Upon internalization, CHIKV traffics through the endosomal pathway towards early 220 
endosomes where membrane fusion occurs (12). To assess whether 5-NT interferes with 221 
virus internalization and/or membrane hemifusion, we next applied a microscopic virus 222 
internalization/hemifusion assay using DiD-labeled CHIKV particles (12, 29, 30). Herein, 223 
membrane hemifusion is evident as an increase in fluorescent activity by dequenching of 224 
the DiD probe due to dilution within cellular membranes. Membrane hemifusion is a 225 
temporary stage prior to fusion pore formation at which the apposed leaflets of the viral 226 
membrane and the endosomal membrane have already merged yet the inner leaflets of 227 
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the lipid membranes are still intact (31). In this assay, the total extent of DiD fluorescence 228 
is thus taken as a measure of internalization/hemifusion. U-2 OS cells were pretreated 229 
with 5-NT or vehicle control DMSO for 1 h and challenged with DiD-labeled CHIKV 230 
particles for 20 min in presence of 5-NT or DMSO. This time-point was chosen as our 231 
previous studies revealed that 90% of all hemifusion events occur within the first 20 min 232 
post-infection (12). Fig 5A shows representative images for all treatment conditions. As a 233 
positive control fusion-inactive DEPC-treated CHIKV was used (12). Quantification of the 234 
total DiD fluorescence intensity in 15 randomly selected images revealed that there are 235 
no differences in the extent of hemifusion between 5-NT and DMSO treatment conditions 236 
(Fig 5B). Taken together, these results suggest that there is no effect of 5-NT on virus cell 237 
entry and the membrane hemifusion capacity of CHIKV.  238 
 239 
5-NT treatment does not inhibit fusion pore formation and RNA release from 240 
endosomes 241 
To investigate if 5-NT may act at the level of fusion pore formation and 242 
nucleocapsid/RNA delivery into the cell cytosol we separated the cytosol from the 243 
endosomal membranes by cell fractionation and analyzed the location of the viral genome 244 
by RT-qPCR. To this end, U-2 OS cells were pretreated for 1 h with DMSO, 5-NT or 245 
bafilomycin A1, an inhibitor of the vacuolar H+ ATPase required for membrane fusion. 246 
Subsequently, the cells were incubated with CHIKV at 37⁰C for 1.5 h in the presence and 247 
absence of the compound after which the cells were washed thoroughly. Thereafter, the 248 
cells were permeabilized with 50µM digitonin for 5 min at RT and cells were incubated for 249 
30 min on ice to allow cytoplasmic proteins to diffuse into the supernatant. The 250 
supernatant (cytoplasmic fraction; indicative for nucleocapsid/RNA delivery) and extracted 251 
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cells (endosomal membrane fraction; non-fused particles) were collected for RNA 252 
isolation and the number of GECs were assessed. The results of another study performed 253 
by us implicates that digitonin treatment does not disrupt the hemifusion intermediate, 254 
indicating that the cytosolic fraction only contains RNA from particles that induced 255 
complete membrane fusion (32). In addition, we subjected both cellular fractions to SDS-256 
page and western blotting to verify the efficiency of fractionation (Fig 6A). Herein, we used 257 
GAPDH as a marker for the cytoplasmic fraction and the endosomal markers EEA1 and 258 
Rab5 were used for the membrane fraction. Fractionation was very efficient with 82% ± 259 
1.4% of GAPDH and 77% ± 9.7% of Rab5 ending up in the cytoplasmic and membrane 260 
fraction based on three independent experiments, respectively. Subsequent quantification 261 
of the GECs in the membrane and cytoplasmic fraction revealed that bafilomycin A1 262 
treatment abolished RNA delivery into the cytosolic fraction with 0.92 ± 0.04 fold (Fig 6B). 263 
Importantly, 5-NT treatment did not interfere with RNA delivery as comparable GECs 264 
levels were found in the cytosolic fraction of control-treated cells. In conclusion, 5-NT does 265 
not inhibit membrane fusion and the nucleocapsid/RNA is efficiently released from the 266 
endosomal membranes into the cytoplasm.  267 
 268 
5-HT receptor antagonist inhibits CHIKV via a different route than 5-NT 269 
The above data shows that 5-NT does not interfere with the initial stages of CHIKV 270 
cell entry which is in contrast to what has been described for reovirus (22). In this work 271 
the authors also used methiothepin mesylate (MM), which is a 5-HT receptor antagonist 272 
blocking 5-HT1/6/7 receptors (33, 34) and showed that MM enhanced reovirus infectivity. 273 
In an attempt to better understand the above differences we next investigated the role of 274 
MM in CHIKV infectivity in U-2 OS cells. First, we assessed the cellular cytotoxicity of MM 275 
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in U-2 OS cells and revealed that MM is non-toxic to the cells at the concentrations used 276 
in this study (Fig 7A). Intriguingly, and in contrast to data described for reovirus, we found 277 
a clear dose-dependent reduction in the number of CHIKV-infected cells with 97% ± 1.0% 278 
inhibition at 10µM MM (Fig 7B). Due to these contrasting data, we also measured the 279 
effect of another 5-HT1A/1B receptor antagonist, isamoltane, on CHIKV infectivity. We 280 
chose isamoltane as it has been shown to antagonize signaling pathways downstream of 281 
5-NT at concentrations ranging from 0.01-10μM (35). Our results show that isamoltane is 282 
non-toxic to cells at this concentration range (Fig 7C) and does not affect CHIKV infectivity 283 
(Fig 7D). This also suggests that the inhibitory effect of MM is independent of 5-HT1A/1B 284 
receptor signaling. Importantly, the above data demonstrates that 5-HT agonist and 285 
antagonists do not have opposing effects on CHIKV infectivity rather 5-NT as well as MM 286 
appear to both act as host-directed antivirals. Given the antiviral role of MM, we next 287 
investigated how it interferes with CHIKV infection using similar methods as described 288 
above for 5-NT. Time-of-addition experiments revealed that the strongest inhibitory effect 289 
(87% ±5.9% reduction) on CHIKV infection is seen when MM is present pre- and during 290 
virus adsorption (Fig 7E). Contradictory to 5-NT, pretreatment with MM alone barely 291 
inhibited CHIKV infection (20% ± 5.5% reduction), indicating that MM needs to be present 292 
during CHIKV adsorption to exert its effect. Indeed, MM treatment during CHIKV 293 
adsorption resulted in a reduction of 70% ± 3.7%. Lastly, 30% ± 7.6% reduction was seen 294 
when MM was added at post-adsorption conditions. Collectively, the results show that 295 
MM, like 5-NT, predominantly interferes with the early steps in infection. Therefore, we 296 
next assessed the capacity of CHIKV to bind cells in the presence of MM. In line with the 297 
results obtained for 5-NT, no differences in virus-cell binding were observed in the 298 
presence or absence of MM (Fig 8A/B). Notably, however, the presence of MM did reduce 299 
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the total extent of hemifusion activity by 54% ± 11% when compared to the non-treated 300 
control suggesting that MM is likely to interfere with internalization and/or membrane 301 
hemifusion activity of the virus (Fig 8C). The extent of fusion was comparable to that of 302 
cells treated with NH4CL (Fig 8C). In line with these results, subsequent cellular fraction 303 
experiments revealed that the levels of cytosolic gRNA are reduced to 0.38 ± 0.29 fold 304 
compared to the control (Fig 8D). Collectively, this data clearly indicates that 5-NT and 305 
MM exert different mechanisms for their antiviral activity in CHIKV replication. 306 
 307 
Discussion 308 
In this study we aimed to understand the efficacy and mode of action of 309 
serotonergic drugs in CHIKV infection. We focused on the 5-HT receptor agonist 5-NT 310 
and 5-HT antagonists, MM and isamoltane. Intriguingly, we observed a strong antiviral 311 
effect of both 5-NT and MM on CHIKV infection whereas no effect was seen for 312 
isamoltane. We show that 5-NT and MM interfere with distinct steps in the replication cycle 313 
of CHIKV.  314 
 Addition of 5-NT to cells led to a stark reduction in the number of infected cells and 315 
lowered the secretion of progeny virions. Detailed analysis of steps of the replication cycle 316 
revealed that 5-NT did not interfere with CHIKV attachment, internalization, hemifusion 317 
activity and gRNA delivery to the cell cytosol. Interestingly, however, we also observed 318 
that upon transfection of RNA transcripts in 5-NT treated cells, the antiviral activity of 5-319 
NT is almost completely diminished. We have two possible explanations for these 320 
intriguing findings. First, even though we do not notice an effect on gRNA delivery to the 321 
cell cytosol, we do not know whether the gRNA is still part of the nucleocapsid or not. 322 
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Thus, based on our findings we hypothesize that 5-NT interferes with nucleocapsid 323 
uncoating, thereby reducing the chance to productively infect a cell. The process of 324 
nucleocapid uncoating is currently ill-understood and early data suggests that ribosomes 325 
are involved in this process (36). However, it has been speculated that as yet unknown 326 
host-factors might further contribute to nucleocapsid uncoating (36, 37). Indeed, more 327 
recent evidence suggest that ubiquitination and cytoskeleton-associated motor proteins 328 
are important for nucleocapsid disassembly in dengue virus, HIV-1 and Influenza A virus 329 
infections (38–42). Alternatively, 5-NT stimulation of 5-HT receptors may affect the 330 
transport/cellular location of CHIKV-containing endosomes thereby releasing the 331 
nucleocapsid at sites that do not support efficient translation and replication of the 332 
genome. Indeed, Mainou and colleagues showed that 5-NT treatment did alter the 333 
distribution of Rab5 endosomes in CCL2 Hela cells (24).  334 
In this study we also demonstrate that MM behaves as a strong antiviral compound 335 
and predominantly controls infectivity after virus cell binding but prior to fusion pore 336 
formation and gRNA delivery. Although MM is mainly reported as an antagonist of the 5-337 
HT1b receptor, it also has nonselective properties and can bind to several other receptors 338 
subtypes, including 5-HT6/7 receptors (33, 43, 44). For example, MM has been described 339 
to function as an inverse agonist inducing desensitization of forskolin-stimulated cAMP 340 
formation in 5-HT7 receptor overexpressed cells (43–45). The lack of antiviral activity of 341 
isamoltane strengthens the notion that CHIKV infectivity is not controlled by antagonizing 342 
the 5-HT1B receptor. MM and isamoltane are both described as 5-HT1B receptor 343 
antagonists yet have distinct alternative effects. For example, isamoltane and MM have 344 
been shown to act differentially to the forskolin-induced cAMP formation in renal epithelial 345 
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cells (46). Future research is required to delineate the precise functions of MM in cells and 346 
how it controls CHIKV internalization and/or the process of membrane hemifusion.  347 
 Many chemical compound library screen studies have revealed that agonist and 348 
antagonist serotonergic drugs can interfere with viral infections (22, 23, 47, 48). For many 349 
of these compounds the mechanism of action remains unclear, but many seems to act on 350 
cell entry of viruses. For example, in hepatitis C virus infection, 5-HT2 receptor antagonists 351 
inhibited cell entry at a late endocytic stage. This has been linked to alterations in the 352 
protein kinase A (PKA) pathway which interfered with claudin 1, an important receptor for 353 
post-binding steps of hepatitis C virus cell entry (17, 47). For JC polyomavirus, 5-HT2 354 
receptor antagonists inhibited infection due to interference of binding of β-arrestin to the 355 
5-HT2A receptors, which is required for internalization of the virus via clathrin-coated 356 
vesicles (20, 49, 50). During reovirus infection, 5-NT strongly inhibited the cell entry of 357 
reovirus whereas MM enhanced reovirus infectivity. This is contradictory to what we 358 
observed for CHIKV and this is likely related to differences in the virus cell entry process 359 
between both viruses. Reovirus particles traffic towards late endosomes where cathepsin-360 
mediated proteolysis is required for efficient infection whereas CHIKV fusion is solely 361 
dependent on low pH and is triggered from within early endosomes (51). Thus, these 362 
serotonergic drugs may regulate a host factor that is beneficial for one virus and inhibitory 363 
for the other.  364 
The wide spread abundance of serotonin receptors in the periphery and the potent 365 
effect of serotonergic drugs on CHIKV infectivity as described in this study suggest that 366 
targeting 5-HT receptors might be an interesting approach to alleviate CHIKV disease. 367 
Pharmacological targeting of specific 5-HT receptors is, however, challenging due to the 368 
various roles of these receptors in multiple parts of the body. To minimize the chance of 369 
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side-effects it is probably best to use combination treatments with low-concentrations of 370 
multiple serotonergic drugs acting on different stages of infection. This will also further 371 
reduce the chance of developing resistance to the treatment. Future studies should be 372 
performed to investigate the in vivo efficacy of single and combination serotonergic drug 373 

















Materials and Methods 377 
Cells, compounds, and cell viability 378 
Human bone osteosarcoma epithelial U-2 OS cells (a gift from the department of 379 
Cell Biology, University Medical Center Groningen, Groningen, The Netherlands) were 380 
maintained in Dulbecco’s modified Eagle medium (DMEM) (Gibco, the Netherlands), high 381 
glucose, GlutaMAX supplemented with 10% fetal bovine serum (FBS) (Life Science 382 
Production, Barnet, United Kingdom). Green monkey kidney Vero-WHO cells (European 383 
Collection of Cell Culture #88020401) were cultured in DMEM supplemented with 5% 384 
FBS. Baby hamster kidney cells (BHK-21 cells; ATCC CCL-10) were cultured in RPMI 385 
medium (Gibco) supplemented with 10% FBS. All media was supplemented with penicillin 386 
(100 U/ml), and streptomycin (100 U/ml) (Gibco). All cells were tested Mycoplasma 387 
negative and maintained at 37°C under 5% CO2.  388 
Ammonium chloride (NH4Cl) (Merck, Darmstadt, Germany) was diluted to a 1M 389 
stock concentration in H2O. Bafilomycin A1 was diluted to a 200mM stock in dimethyl 390 
sulfoxide (DMSO). 5-nonyloxytryptamine oxalate (5-NT) (Tocris, Bristol, United Kingdom) 391 
was diluted to a 5mM stock concentration in DMSO (Merck). Methiothepin mesylate (MM) 392 
(Tocris) was diluted to a 10mM stock concentration in H2O. All chemicals were stored 393 
according to the manufacturer’s instructions. 394 
Cytotoxicity of the compounds were tested by use of a MTT [3-(4,5-dimethyl-2- 395 
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] assay (Merck) at a final MTT 396 
concentration of 0.45 mg/ml or by use of a ATPlite Luminescence Assay System 397 
(PerkinElmer, Waltham, Massachusetts, United States) according to the manufacturer’s 398 
instructions. 399 
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RT-qPCR of serotonin receptors 401 
RNA was isolated from U-2 OS cells with the RNeasy minikit (Qiagen, Hilden, 402 
Germany). 0.5µg RNA was reverse transcribed into cDNA using the PrimeScript RT 403 
Reagent Kit (Takara, Kusatsu, Japan). Real-time qPCR was conducted on a Stepone plus 404 
real-time PCR system from Applied Biosystems using specific primers (Table 1) 405 
(Eurogentec, Seraing, Belgium), SYBR green reagents and ROX reference dye (Thermo 406 
Scientific, Waltham, Massachusetts, United States). The cDNA was diluted 1:10 for the 407 
amplification with GAPDH-specific primers. Data was analyzed using StepOne™V2.3 408 
software.  409 
 410 
Virus production, purification and quantification 411 
The infectious clone based on CHIKV strain La Reunion (LR) 2006 OPY1 was 412 
kindly provided by prof. Andres Merits (University of Tartu, Tartu, Estonia). CHIKV-LR 413 
5’GFP was kindly provided by the European Virus Archive (EVA, Marseille, France). GFP 414 
is cloned after a second subgenomic promotor 5’ to the structural genes (52). Virus 415 
production was done as described previously (12, 53). Briefly, BHK-21 cells were 416 
transfected with in vitro-transcribed RNA transcripts by electroporation with a Gene Pulser 417 
Xcell system (1.5 kV, 25µF and 200Ω) (Bio-Rad, Hercules, California, United States). At 418 
22 h post-transfection, the supernatant was harvested (p0) and used to inoculate Vero-419 
WHO cells at a multiplicity of infection (MOI) of 0.01 (p1) to generate working stocks.  420 
Purified virus was prepared by inoculating monolayers of BHK-21 cells with CHIKV-421 
LR (p0) at MOI 4. At 25 hours post-infection (hpi), the supernatant was harvested and 422 
cleared from cell debris by low-speed centrifugation. Subsequently, the virus particles 423 
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were pelleted by ultracentrifugation in a Beckman type 19 rotor (Beckman Coulter, Brea, 424 
California, United States) at 54,000xg for 2.5 h at 4°C. The pellet was resuspended 425 
overnight in HNE buffer (5mM HEPES (Gibco), 150mM NaCl (Merck), 0.1mM EDTA [pH 426 
7.4] (Merck)) before it was purified by ultracentrifugation on a sucrose density gradient (20 427 
to 50% [w/v] sucrose in HNE) in a Beckman SW41 rotor at 75,000xg for 18 h at 4°C. Upon 428 
centrifugation, the virus particles were in the 40% to 45% sucrose layer, which was 429 
harvested and aliquoted before storage at -80⁰C. 430 
L-[35S]methionine/L-[35S]cysteine-labeled CHIKV was produced by inoculation of a 431 
confluent monolayer of BHK-21 cells with CHIKV-LR (p0) at MOI 10. At 2.5 hpi, the BHK-432 
21 cells were starved for 1.5 h with DMEM without cysteine/methionine (Gibco) at 37°C. 433 
Next, [35S]-EasyTag™ Express Protein Labeling Mix (PerkinElmer) was added and the 434 
cells were incubated overnight at 37°C. The medium was harvested and cell debris was 435 
removed with low-speed centrifugation. Purification was done by ultracentrifugation for 2 436 
h at 154,000xg at 4°C in a SW41 rotor (Beckman) using a two-step sucrose gradient 437 
(20%/50% w/v in HNE). Radioactive virus was collected at the 20%/50% sucrose interface 438 
and radioactivity was counted by liquid scintillation analysis. Fractions were pooled based 439 
on radioactivity counts and stored at -80⁰C. 440 
The infectious virus titers of all virus preparations were determined with a plaque 441 
assay in Vero-WHO cells. Additionally, the number of genome equivalent copies (GECs) 442 
was determined by RT-qPCR, as described previously (11). 443 
 444 
Flow cytometry analysis 445 
Flow cytometry analysis was used to determine the number of infected cells. U-2 446 
OS cells were washed and pre-incubated for 1 h with or without compounds diluted in U-447 
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2 OS medium containing 2% FBS. Thereafter, CHIKV-LR 5’GFP was added to the cells 448 
at the indicated MOI. At 1.5 hpi, inoculum was removed and fresh U-2 OS medium 449 
containing 10% FBS was added in the presence or absence of the compound and 450 
incubated for a specified time point at 37⁰C under 5% CO2. Upon collection, cells were 451 
washed and fixed with 4% paraformaldehyde (PFA) (Alfa Aesar, Haverhill, 452 
Massachusetts, United States) and analyzed by flow cytometry. Flow cytometry was 453 
performed with a FacsVerse (BD Biosciences, Franklin Lakes, New Jersey, United States) 454 
and analyzed with FlowJo vX.0.7. 455 
  456 
Virucidal assay 457 
CHIKV-LR 5’GFP was incubated for 1.5 h at 37⁰C in U-2 OS medium containing 458 
2% FBS and 5µM 5-NT or DMSO in a final volume of 300µL. After incubation, the 459 
infectious titer was determined by plaque assay in Vero-WHO cells. 460 
 461 
Binding assay with 35S-labeled CHIKV 462 
U-2 OS cells were seeded to 80% confluency in a 12-wells plate and washed twice 463 
with HNE supplemented with 0.5 mM CaCl2 (Merck), 0.5 mM MgCl2 (Merck) and 1% FBS 464 
(HNE+). Cells were incubated with HNE+ supplemented with the compounds of interest or 465 
vehicle control for 45 min at 37⁰C and subsequently 15 min at 4⁰C. Next, 1x105 dpm 35S-466 
labeled CHIKV (2.6x108 PFU, corresponding to MOI 500) diluted in HNE+ was added to 467 
the cells and incubated for 3 h at 4⁰C to allow virus cell binding. Unbound virus was 468 
removed by washing two times with HNE+. The cells were harvested by trypsinization and 469 
the total volume was subjected to liquid scintillation analysis to count radioactivity.  470 
 471 
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Binding and internalization assay by RT-qPCR  472 
U-2 OS cells were seeded to 80% confluency in a 24-wells plate and washed three 473 
times with HNE+ before incubation with HNE+ supplemented with the compounds of 474 
interest or vehicle control DMSO for 1 h at 37⁰C. Next, CHIKV-LR was added to the cells 475 
at MOI 5 and incubated at 37⁰C for 1.5 h. Thereafter, unbound virus was removed by 476 
washing three times with PBS (Life Technologies, Carlsbad, California, United States). 477 
Next, cells were lysed with the RNAeasy mini kit (Qiagen) according to manufacturer’s 478 
instructions and the number of GECs were determined, as described before (11). In 479 
addition to this protocol, single-stranded RNA was degraded after cDNA synthesis by 480 
RNAse A (Thermo Scientific). 481 
 482 
Microscopic fusion assay 483 
For the microscopic fusion assay, purified CHIKV particles were labeled with the 484 
lipophilic fluorescent probe 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindodicarbocyanine, 4-485 
chlorobenzenesulfonate salt (DiD) (Life Technologies), as described before (12). U-2 OS 486 
cells were cultured to 80% confluency in Nunc™ 8-well Lab-Tek II Chambered Coverglass 487 
slides (Thermo Scientific). Upon infection, the cells were washed three times with serum-488 
free, phenol red-free MEM (Gibco) medium and incubated with phenol red-free MEM 489 
supplemented with 1% glucose (Merck) and the compounds of interest. After 1 h 490 
treatment, DiD-labeled CHIKV (MOI ~ 10) was added to the cells and incubated at 37⁰C 491 
for 20 min to allow virus cell entry and membrane fusion. Subsequently, unbound particles 492 
were removed by washing three times with serum-free, phenol red-free MEM, after which 493 
fresh phenol-red free MEM supplemented with 1% glucose was added. Image fields were 494 
randomly selected using differential interference contrast (DIC) and 15 snapshots were 495 
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taken per experiment in both the DIC and DiD channels with a Leica Biosystems 6000B 496 
instrument (Leica Biosystems, Amsterdam, The Netherlands). All snapshots were 497 
analyzed for total area of fluorescent spots quantified using the ParticleAnalzer plugin of 498 
ImageJ. Total fluorescent area was averaged per experiment and normalized to the total 499 
fluorescent area of the vehicle control DMSO. 500 
 501 
Cell entry bypass assay 502 
In vitro-transcribed RNA derived from the infectious clone CHIKV-LR was 503 
electroporated in 1x107 U-2 OS cells treated beforehand with 5µM 5-NT or DMSO for 1 h, 504 
using a Gene Pulser Xcell system (250V, 95µF and 186Ω). After electroporation, the cells 505 
were seeded into a 12-wells plate and incubated in medium containing 5-NT at an end 506 
concentration of 5µM or the vehicle control DMSO for 12 h at 37⁰C. Cell supernatants 507 
were harvested and analyzed for infectious particle production with a plaque assay on 508 
Vero-WHO cells. Additionally, the transfected cells were harvested and prepared for flow 509 
cytometry analysis. To this end, cells were fixed with 4% PFA, permeabilized and stained 510 
with a rabbit anti-E2-stem antibody (1:1000; obtained from G. Pijlman, Wageningen 511 
University, Wageningen, The Netherlands) and Alexa Fluor 647-conjugated chicken anti-512 
rabbit antibody (1:300; life Technologies).  513 
  514 
Digitonin-based cell fractionation 515 
Cell fractionation of U-2 OS cells was performed as described previously (54). 516 
Briefly, the cells were seeded to 80% confluency in a 12-wells plate, washed 3 times with 517 
HNE+, and incubated with HNE+ supplemented with the compounds of interest or vehicle 518 
control DMSO for 1 h at 37⁰C. CHIKV-LR was added to the cells at MOI 5 and incubated 519 
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at 37⁰C for 1.5 h after which the inoculum was removed. Cells were first washed with PBS, 520 
treated for 2 min with an high-salt-high-pH buffer i.e., 1M NaCl in H2O [pH 9.5], and then 521 
washed for another three times with PBS. Next, cells were permeabilized by incubation 522 
with 50μg/mL digitonin dissolved in PBS (Sigma-Aldrich, St. Louis, Missouri, United 523 
States) for 5 min at RT and subsequently for 30 min on ice. Directly after this incubation 524 
step, the supernatant was carefully collected to obtain the cytosolic fraction. Thereafter, 525 
the adherent but permeabilized cells were collected and represent the membrane fraction. 526 
RNA was isolated using the viral RNA kit and the RNAeasy mini kit for the cytosolic and 527 
the membrane fraction, respectively, according to manufacturer’s instructions. The 528 
number of GECs were determined, as described before (11). In addition to this protocol, 529 
single-stranded RNA was degraded after cDNA synthesis by RNAse A. Additionally, 530 
western blot analysis was performed to verify the fractionation step. To this end, the 531 
fractions were diluted in 4x SDS sample buffer (Merck) and heated at 95 °C for 5 min prior 532 
to fractionation by SDS-PAGE. The antibodies used were mouse-anti-EEA1 (1:5000; BD 533 
Biosciences), mouse-anti-GAPDH (1:10,0000; Abcam, Cambridge, United Kingdom), 534 
rabbit-anti-Rab5 (1:1000; Abcam). Secondary HRP-conjugated antibodies, anti-mouse or 535 
anti-rabbit (Thermo Fisher Scientific) were used as recommended by manufacturer. 536 
Quantification was done in ImageQuant TL. 537 
 538 
Statistical Analysis 539 
 All data were analyzed in GraphPad Prism software. Data are presented as mean 540 
±SD unless indicated otherwise. Student T test was used to evaluate statistical 541 
differences. P value ≤0.05 was considered significant with *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 542 
0.001 and ***p≤ 0.0001. EC50, the concentration at which 5-NT reduces virus particle 543 
 on A













production by 50% is determined by a dose-response curve that is fitted by lon-linear 544 
regression analysis employing a sigmoidal model.  545 
 546 
Acknowledgments 547 
This work was supported by the Graduate School of Medical Sciences of the 548 
University of Groningen and by a research grant from De Cock-Hadders Stichting of the 549 
University of Groningen (grant to E.M.B). The funders had no role in study design, data 550 
collection and interpretation, or the decision to submit the work for publication. 551 
 552 
References 553 
1.  Weaver SC, Lecuit M. 2015. Chikungunya virus and the global spread of a 554 
mosquito-borne disease. N Engl J Med 372:1231–1239. 555 
2.  Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. 2012. Chikungunya: A re-556 
emerging virus. Lancet 379:662–671. 557 
3.  Suhrbier A, Jaffar-Bandjee M-C, Gasque P. 2012. Arthritogenic alphaviruses—an 558 
overview. Nat Rev Rheumatol 8:420–429. 559 
4.  Rodríguez-Morales AJ, Cardona-Ospina JA, Fernanda Urbano-Garzón S, 560 
Sebastian Hurtado-Zapata J. 2016. Prevalence of Post-Chikungunya Infection 561 
Chronic Inflammatory Arthritis: A Systematic Review and Meta-Analysis. Arthritis 562 
Care Res 68:1849–1858. 563 
5.  Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. 2018. Host-directed 564 
therapies for bacterial and viral infections. Nat Rev Drug Discov 17:35–56. 565 
6.  Tanaka A, Tumkosit U, Nakamura S, Motooka D, Kishishita N, Priengprom T, Sa-566 
 on A













ngasang A, Kinoshita T, Takeda N, Maeda Y. 2017. Genome-Wide Screening 567 
Uncovers the Significance of N-Sulfation of Heparan Sulfate as a Host Cell Factor 568 
for Chikungunya Virus Infection. J Virol 91:1–22. 569 
7.  Karlas A, Berre S, Couderc T, Varjak M, Braun P, Meyer M, Gangneux N, Karo-570 
Astover L, Weege F, Raftery M, Schönrich G, Klemm U, Wurzlbauer A, Bracher F, 571 
Merits A, Meyer TF, Lecuit M. 2016. A human genome-wide loss-of-function 572 
screen identifies effective chikungunya antiviral drugs. Nat Commun 7:11320. 573 
8.  De Clercq E, Li G. 2016. Approved antiviral drugs over the past 50 years. Clin 574 
Microbiol Rev. 575 
9.  Ching K-C, F. P. Ng L, Chai CLL. 2017. A compendium of small molecule direct-576 
acting and host-targeting inhibitors as therapies against alphaviruses. J Antimicrob 577 
Chemother 2973–2989. 578 
10.  Zhang R, Kim AS, Fox JM, Nair S, Basore K, Klimstra WB, Rimkunas R, Fong RH, 579 
Lin H, Poddar S, Crowe JE, Doranz BJ, Fremont DH, Diamond MS. 2018. Mxra8 580 
is a receptor for multiple arthritogenic alphaviruses. Nature 557:570–574. 581 
11.  Van Duijl-Richter MKS, Blijleven JS, van Oijen AM, Smit JM. 2015. Chikungunya 582 
virus fusion properties elucidated by single-particle and bulk approaches. J Gen 583 
Virol 96:2122–2132. 584 
12.  Hoornweg TE, van Duijl-Richter MKS, Ayala Nuñez N V., Albulescu IC, van 585 
Hemert MJ, Smit JM. 2016. Dynamics of Chikungunya Virus Cell Entry Unraveled 586 
by Single-Virus Tracking in Living Cells. J Virol 90:4745–4756. 587 
13.  Solignat M, Gay B, Higgs S, Briant L, Devaux C. 2009. Replication cycle of 588 
chikungunya: A re-emerging arbovirus. Virology 393:183–197. 589 
14.  Silva LA, Dermody TS. 2017. Chikungunya virus: Epidemiology, replication, 590 
 on A













disease mechanisms, and prospective intervention strategies. J Clin Invest. 591 
15.  Sodhi A, Montaner S, Gutkind JS. 2004. Viral hijacking of G-protein-coupled-592 
receptor signalling networks. Nat Rev Mol Cell Biol 5:998–1012. 593 
16.  Zhang N, Huang H, Tan B, Wei Y, Xiong Q, Yan Y, Hou L, Wu N, Siwko S, 594 
Cimarelli A, Xu J, Han H, Qian M, Liu M, Du B. 2017. Leucine-rich repeat-595 
containing G protein– coupled receptor 4 facilitates vesicular stomatitis virus 596 
infection by binding vesicular stomatitis virus glycoprotein. J Biol Chem 597 
292:16527–16538. 598 
17.  Cao L, Chen J, Wang Y, Yang Y, Qing J, Rao Z, Chen X, Lou Z. 2018. 599 
Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical 600 
biology strategy. Protein Cell. 601 
18.  Duman RS. 1998. Novel therapeutic approaches beyond the serotonin receptor. 602 
Biol Psychiatry. 603 
19.  Hannon J, Hoyer D. 2008. Molecular biology of 5-HT receptors. Behav Brain Res 604 
195:198–213. 605 
20.  Assetta B, Maginnis MS, Gracia Ahufinger I, Haley SA, Gee G V., Nelson CDS, 606 
O’Hara BA, Allen Ramdial S -a. A, Atwood WJ. 2013. 5-HT2 Receptors Facilitate 607 
JC Polyomavirus Entry. J Virol 87:13490–13498. 608 
21.  Manéglier B, Guillemin GJ, Clayette P, Rogez-Kreuz C, Brew BJ, Dormont D, 609 
Advenier C, Therond P, Spreux-Varoquaux O. 2008. Serotonin decreases HIV-1 610 
replication in primary cultures of human macrophages through 5-HT(1A) 611 
receptors. Br J Pharmacol 154:174–82. 612 
22.  Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, 613 
Rong L. 2015. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled 614 
 on A













Receptor Antagonists. J Virol 89:9932–9938. 615 
23.  Ashbrook AW, Lentscher AJ, Zamora PF, Silva LA, May NA, Bauer JA, Morrison 616 
TE, Dermody TS. 2016. Antagonism of the sodium-potassium ATPase impairs 617 
chikungunya virus infection. MBio 7:1–14. 618 
24.  Mainou B a., Ashbrook AW, Smith EC, Dorset DC, Denison MR, Dermody TS. 619 
2015. Serotonin Receptor Agonist 5-nonyloxytryptamine Alters the Kinetics of 620 
Reovirus Cell Entry. J Virol 89:JVI.00739-15. 621 
25.  Glennon RA, Hong SS, Dukat M, Teitler M, Davis K. 1994. 5-622 
(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor 623 
agonist. J Med Chem 37:2828–2830. 624 
26.  van Duijl-Richter MKS, Hoornweg TE, Rodenhuis-Zybert IA, Smit JM. 2015. Early 625 
events in chikungunya virus infection—from virus cell binding to membrane fusion. 626 
Viruses 7:3647–3674. 627 
27.  Chen W, Foo S-S, Rulli NE, Taylor A, Sheng K-C, Herrero LJ, Herring BL, Lidbury 628 
BA, Li RW, Walsh NC, Sims NA, Smith PN, Mahalingam S. 2014. Arthritogenic 629 
alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. 630 
Proc Natl Acad Sci 111:6040–6045. 631 
28.  Wang G, Hernandez R, Weninger K, Brown DT. 2007. Infection of cells by Sindbis 632 
virus at low temperature. Virology. 633 
29.  Ayala-Nunez N V., Hoornweg TE, van de Pol DPI, Sjollema KA, Flipse J, van der 634 
Schaar HM, Smit JM. 2016. How antibodies alter the cell entry pathway of dengue 635 
virus particles in macrophages. Sci Rep 6:28768. 636 
30.  Ayala-Nuñez N V., Wilschut J, Smit JM. 2011. Monitoring virus entry into living 637 
cells using DiD-labeled dengue virus particles. Methods 55:137–143. 638 
 on A













31.  Harrison SC. 2015. Viral membrane fusion. Virology. 639 
32.  Hoornweg TE, Bouma EM, van de Pol DPI, Rodenhuis-Zybert IA, Smit JM. 2020. 640 
Chikungunya virus requires an intact microtubule network for efficient viral 641 
genome delivery. bioRxiv 2020.03.24.004820. 642 
33.  Jin H, Oksenberg D, Ashkenazi A, Peroutka SJ, Duncan AMV, Rozmahel R, Yang 643 
Y, Mengod G, Palacios JM, O’Dowd BF. 1992. Characterization of the human 5-644 
hydroxytryptamine(1B) receptor. J Biol Chem 267:5735–5738. 645 
34.  Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL. 1993. 646 
Cloning of a novel human serotonin receptor (5-HT 7 ) positively linked to 647 
adenylate cyclase. J Biol Chem 268:23422–23426. 648 
35.  McDuffie JE, Motley ED, Limbird EL, Maleque MA. 2000. 5-Hydroxytryptamine 649 
stimulates phosphorylation of p44/p42 mitogen- activated protein kinase activation 650 
in bovine aortic endothelial cell cultures. J Cardiovasc Pharmacol 35:398–402. 651 
36.  Singh I, Helenius A. 1992. Role of ribosomes in Semliki Forest virus nucleocapsid 652 
uncoating. J Virol 66:7049–58. 653 
37.  Wengler G. 2009. The regulation of disassembly of alphavirus cores. Arch Virol 654 
154:381–390. 655 
38.  Yamauchi Y, Greber UF. 2016. Principles of Virus Uncoating: Cues and the 656 
Snooker Ball. Traffic 17:569–592. 657 
39.  Banerjee I, Miyake Y, Philip Nobs S, Schneider C, Horvath P, Kopf M, Matthias P, 658 
Helenius A, Yamauchi Y. 2014. Influenza A virus uses the aggresome processing 659 
machinery for host cell entry. Science (80- ) 346:473–477. 660 
40.  Francis AC, Melikyan GB. 2018. Live-cell imaging of early steps of single HIV-1 661 
infection. Viruses. 662 
 on A













41.  Lukic Z, Dharan A, Fricke T, Diaz-Griffero F, Campbell EM. 2014. HIV-1 Uncoating 663 
Is Facilitated by Dynein and Kinesin 1. J Virol 88:13613–13625. 664 
42.  Malikov V, Da Silva ES, Jovasevic V, Bennett G, De Souza Aranha Vieira DA, 665 
Schulte B, Diaz-Griffero F, Walsh D, Naghavi MH. 2015. HIV-1 capsids bind and 666 
exploit the kinesin-1 adaptor FEZ1 for inward movement to the nucleus. Nat 667 
Commun 6. 668 
43.  McLoughlin DJ, Strange PG. 2000. Mechanisms of agonism and inverse agonism 669 
at serotonin 5-HT(1A) receptors. J Neurochem 74:347–357. 670 
44.  Schoeffter P, Ullmer C, Bobirnac I, Gabbiani G, Lübbert H. 1996. Functional, 671 
endogenously expressed 5-hydroxytryptamine 5-ht7 receptors in human vascular 672 
smooth muscle cells. Br J Pharmacol 117:993–994. 673 
45.  Krobert KA, Andressen KW, Levy FO. 2006. Heterologous desensitization is 674 
evoked by both agonist and antagonist stimulation of the human 5-HT7 serotonin 675 
receptor. Eur J Pharmacol 532:1–10. 676 
46.  Pauwels PJ, Palmier C. 1994. Inhibition by 5-HT of forskolin-induced cAMP 677 
Formation in the renal opossum Epithelial cell line OK: Mediation by a 5-HT1B like 678 
receptor and antagonism by methiothepin. Neuropharmacology. 679 
47.  Vandeputte A, Fénéant L, Helle F, Rouillé Y, Song O, Baumert TF, Dubuisson J, 680 
Brodin P, Bukh J, Cocquerel L, L’homme L, Belouzard S, Prentoe J, Gattolliat C-681 
H, Riva L, Asselah T. 2018. Identification of Piperazinylbenzenesulfonamides as 682 
New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry. J Virol 92:1–683 
19. 684 
48.  Barrows NJ, Campos RK, Powell ST, Routh A, Bradrick SS, Garcia-blanco MA, 685 
Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-lerner G. 2016. 686 
 on A













Resource A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection 687 
Resource A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection 688 
259–270. 689 
49.  Assetta B, Morris-Love J, Gee G V., Atkinson AL, O’Hara BA, Maginnis MS, Haley 690 
SA, Atwood WJ. 2019. Genetic and Functional Dissection of the Role of Individual 691 
5-HT 2 Receptors as Entry Receptors for JC Polyomavirus. Cell Rep 27:1960–692 
1966.e6. 693 
50.  Mayberry CL, Soucy AN, Lajoie CR, DuShane JK, Maginnis MS. 2019. JC 694 
Polyomavirus Entry by Clathrin-Mediated Endocytosis Is Driven by β-Arrestin. J 695 
Virol 93. 696 
51.  Mainou BA, Dermody TS. 2012. Transport to Late Endosomes Is Required for 697 
Efficient Reovirus Infection. J Virol. 698 
52.  Tsetsarkin K, Higgs S, Gee CEMC, Lamballerie XDE, Charrel RN, Vanlandingham 699 
DL. 2006. Research Paper 6. 700 
53.  Scholte FEM, Tas A, Martina BEE, Cordioli P, Narayanan K, Makino S, Snijder EJ, 701 
van Hemert MJ. 2013. Characterization of Synthetic Chikungunya Viruses Based 702 
on the Consensus Sequence of Recent E1-226V Isolates. PLoS One 8. 703 
54.  Fahrer J, Rausch J, Barth H. 2013. A Cell-Permeable Fusion Protein Based on 704 
Clostridium botulinum C2 Toxin for Delivery of p53 Tumorsuppressor into Cancer 705 


















Fig 1. Serotonin receptor agonist 5-NT strongly inhibits CHIKV infection. (A) Delta 710 
Ct values between 5-HT receptors and GAPDH mRNA expression in U-2 OS cells. RNA 711 
derived from U-2 OS cell lysates was reverse transcribed into cDNA and subjected to 712 
qPCR with specific primers for 10 subtypes of the serotonin receptor family and GAPDH 713 
(1:10 dilution) as reference gene. Three independent experiments were performed, each 714 
in duplicate. Each dot represents the average of an independent experiment. (B) MTT 715 
assay to determine the cytotoxicity of 5-NT in U-2 OS cells. Cells were treated for 21 h in 716 
the absence or presence of increasing concentrations of the inhibitor to mimic conditions 717 
during the infectivity assay. Dotted line indicates 75% cell survival. Three independent 718 
experiments were performed, each in sextuplicate. (C, D) U-2 OS cells were pretreated 719 
for 1 h with the vehicle control DMSO, 75mM NH4Cl or increasing concentrations of 5-NT 720 
and subsequently challenged with CHIKV-LR 5’GFP at MOI 5 for 20 h. Three independent 721 
experiments were performed with one replicate per experiment. (C) Cells were collected 722 
for analysis with flow cytometry for GFP-positive cells and (D) supernatants were 723 
harvested and virus particle production was analyzed by plaque assay on Vero-WHO 724 
cells. (A-D) Each dot represents an independent experiment. Bars and error bars 725 
represent means and SDs of the experiments, respectively. Statistics was done by use of 726 
the student T-test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ***p≤ 0.0001). NT, non-treated; 727 
ns, non-significant.  728 
 729 
Fig 2. 5-NT inhibits CHIKV infection early in the replication cycle. (A) CHIKV-LR 730 
5’GFP was incubated for 1.5 h at 37⁰C in U-2 OS medium containing 2% FBS and 5µM 731 
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5-NT or vehicle control DMSO in a final volume of 300µL. After incubation, the infectious 732 
titer was determined by plaque assay in Vero-WHO cells. Three independent experiments 733 
were performed with one replicate per experiment. (B) Growth curve analysis of CHIKV 734 
infection. U-2 OS cells were infected with CHIKV-LR 5’GFP at MOI 5. Cells and 735 
supernatant was collected at 4, 6, 8, 10 and 12hpi to determine GFP-positive cells using 736 
flow cytometry (light grey bars) and infectious virus particle production using a plaque 737 
assay on Vero-WHO cells (dark grey bars), respectively. Dotted line represents the 738 
detection limit of the plaque assay. Two independent experiments were performed, each 739 
in duplicate. (C) Schematic representation of the time-of-addition assay. (D) U-2 OS cells 740 
were treated for the indicated time-points with vehicle control DMSO or 5µM 5-NT. Virus 741 
adsorption was allowed for 1.5 h after which the inoculum was removed. U-2 OS cells 742 
were collected at 10 hpi and analyzed for GFP-positive cells using flow cytometry. Three 743 
independent experiments were performed with one replicate per experiment. The 744 
interpretation of each dot, bar, error bar and statistics is explained in the legend to Figure 745 
1. 746 
 747 
Fig 3. The antiviral activity of 5-NT is before viral genome delivery. (A, B) U-2 OS 748 
cells were pretreated with 5-NT or vehicle control DMSO for 1 h before in vitro transcribed 749 
viral RNA was transfected by electroporation. Cells were cultured for 12 h with or without 750 
5-NT. (A) Supernatants were harvested and virus particle production was determined with 751 
a plaque assay on Vero-WHO cells. Three independent experiments were performed, 752 
each in duplicate (B) Cells were collected for analysis with flow cytometry for GFP-positive 753 
cells. Three independent experiments were performed, each in duplicate (C) U-2 OS cells 754 
were pretreated with 5µM 5-NT or vehicle control DMSO for 1 h before infection with 755 
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CHKV-LR 5’GFP at MOI 60. Supernatants were harvested after 10 hpi and virus particle 756 
production was determined with a plaque assay on Vero-WHO cells. Four independent 757 
experiments were performed, each in duplicate. The interpretation of each dot, bar, error 758 
bar and statistics is explained in the legend to Figure 1. 759 
 760 
Fig 4. Binding of CHIKV is not altered in 5-NT treated cells. (A) Binding of CHIKV to 761 
U-2 OS cells was tested using 35S-labeled CHIKV particles. 35S-labeled CHIKV was 762 
incubated for 3 h at 4⁰C in the presence and absence of 5 µM 5-NT with U-2 OS cells. 763 
The cells were washed to remove unbound virus particles, harvested and radioactivity 764 
was counted. Three independent experiments were performed, each in duplicate. (B) 765 
Binding CHIKV particles in 5 µM 5-NT or vehicle control DMSO treated U-2 OS cells. 766 
Incubation was done for 1.5 h at 37⁰C. The cells were washed to remove unbound virus 767 
particles and collected to determine total number of viral GECs with specific primers 768 
against the viral genome. Three independent experiments were performed, each in 769 
duplicate. The interpretation of each dot, bar, error bar and statistics is explained in the 770 
legend to Figure 1. 771 
 772 
Fig 5. 5-NT does not interfere with the membrane fusion capacity of CHIKV. U-2 OS 773 
cells were pretreated with 5 µM 5-NT or vehicle control DMSO for 1 h and incubated for 774 
20 minutes with DID-labeled CHIKV particles in presence of 5-NT or DMSO. After washing 775 
to remove unbound virus particles, the extent of membrane hemifusion was measured in 776 
15 randomly taken microscopic images per experiment. (A) Representative images 777 
showing the DiD signal in DMSO and 5-NT treated U-2 OS cells and for DEPC-inactivated 778 
CHIKV. White bar represents 10µm. (B) The total extent of fusion is normalized to that of 779 
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the non-treated positive control (DMSO). Three independent experiments were 780 
performed, each in duplicate. The interpretation of each dot, bar, error bar and statistics 781 
is explained in the legend to Figure 1. 782 
 783 
Fig 6. Genomic RNA delivery to cytoplasm upon 5-NT treatment. Pretreated U-2 OS 784 
cells with vehicle control DMSO, 5-NT, or Bafilomycin A1 (BafA1) were infected with 785 
CHIKV-LR OPY1 2006 at MOI 5 for 1.5 h at 37⁰C. The cells were washed and 786 
permeabilized using 50µg/ml digitonin for 5 min at RT and 30 min on ice. Separation of 787 
the cytoplasmic fraction from the membrane fraction was assessed by western blot. 788 
Subsequently, the total number of GECs were determined in the cytoplasmic and the 789 
membrane fraction. (A) Representative western blot image of the separation. In total three 790 
independent experiments were performed. Shown is GAPDH which represents the 791 
cytoplasmic fraction (C) and EEA1 and Rab5 which represent the membrane fraction (M) 792 
from the extracted cells. (B) Total number of viral GEC was assessed by RT-qPCR after 793 
western blot confirmation of successful fractionation. Fold change of cytoplasmic fraction 794 
of total gRNA copies is shown. Three independent experiments were performed, each in 795 
duplicate. The interpretation of each dot, bar, error bar and statistics is explained in the 796 
legend to Figure 1. 797 
 798 
Fig 7. MM inhibits CHIKV infection early in CHIKV infection. (A) MTT assay to 799 
determine the cytotoxicity of MM to U-2 OS cells. Cells were treated for 21 h in the 800 
presence of increasing concentrations of the inhibitor to mimic conditions during the 801 
infectivity assay. Dotted line indicates 75% survival rate. Three independent experiments 802 
were performed, each in sextuplicate. (B, D) U-2 OS cells were pretreated for 1 h with 803 
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75mM NH4Cl or increasing concentrations of (B) MM or (D) isamoltane and subsequently 804 
challenged with CHIKV-LR 5’GFP at MOI 5 for 20 h. U-2 OS cells were collected and 805 
analyzed with flow cytometry for GFP-positive cells. Three independent experiments were 806 
performed with one replicate per experiment. (C) ATPlite assay to determine the 807 
cytotoxicity of isamoltane to U-2 OS cells. Cells were treated for 21 h in the presence of 808 
increasing concentrations of the inhibitor to mimic conditions during the infectivity assay. 809 
Dotted line indicates 75% survival rate. Three independent experiments were performed, 810 
each in duplicate. (E) U-2 OS cells were treated for the time-points indicated in Fig 2A 811 
with or without 10µM MM. Virus adsorption was allowed for 1.5 h after which the inoculum 812 
was removed. U-2 OS cells were collected at 10 hpi and analyzed with flow cytometry for 813 
GFP-positive cells. Three independent experiments were performed with one replicate per 814 
experiment. The interpretation of each dot, bar, error bar and statistics is explained in the 815 
legend to Figure 1. 816 
 817 
Fig 8. MM inhibits CHIKV infection by restricting membrane fusion activity. (A) 818 
Binding of CHIKV to U-2 OS cells was tested using 35S-labeled CHIKV. Radioactive 819 
labeled virus was incubated for 3 h at 4⁰C with U-2 OS cells pretreated for 1 h with or 820 
without 10µM MM. The cells were washed to remove unbound virus particles and 821 
harvested by trypsinization. The trypsinized suspension was subjected to scintillation 822 
counting. Three independent experiments were performed, each in duplicate. (B) Binding 823 
and internalization of CHIKV particles. Pretreated U-2 OS cells with or without 10µM MM 824 
for 1 h were infected with CHIKV-LR for 1.5 h at 37⁰C. The cells were washed and total 825 
number of viral GECs were assessed with specific primers against the viral genome. 826 
Three independent experiments were performed, each in duplicate. (C) U-2 OS cells were 827 
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pretreated with 10µM MM or 50mM NH4Cl for 1 h and incubated for 20 min with DID-828 
labeled CHIKV particles in the presence of the compounds. DEPC-inactivated CHIKV was 829 
used as a negative control. After washing to remove unbound virus particles, the extent 830 
of membrane hemifusion was measured in 15 randomly taken microscopic images per 831 
experiment. The total extent of fusion is normalized to that of the non-treated control 832 
(DMSO). Three independent experiments were performed, each in duplicate. (D) gRNA 833 
delivery to cytoplasm upon MM treatment. Total number of viral GECs was assessed by 834 
RT-qPCR. Fold change of cytoplasmic fraction of total gRNA copies is shown. Three 835 
independent experiments were performed, each in duplicate. The interpretation of each 836 
dot, bar, error bar and statistics is explained in the legend to Figure 1.  837 
 838 
Table 1. List of primers used for 5-HT receptor genes. 839 
Gene Size product (bp) Forward primer Reverse primer 
5-HTR1A 132 GGTAACCTGCGACCTGTTCA GGCGTCCTCTTGTTCACGTA 
5-HTR1B 101 GGTAACCTGCGACCTGTTCA GCATCACCAGGATGGACACA 
5-HTR1D 135 GGGCCTTCTACATTCCCTCG CAGAGCCTGTGATGAGGTGG 
5-HTR2A 155 ACTGTGAGAGATGCAGCGAG TTCTCACCAAACCGAGGACAAA 
5-HTR2B 85 ACAGCAGCAAGCAAGTCTAGT CATGCCAGAGAGTTCCCCCT 
5-HTR2C 162 GGCCAGCACTTTCAATCGTC GGGGCATGACAAGTAGTCCC 
5-HTR3 110 CCCTGGTTATGCTCTGGTCC GGGGCCTAAGCAGAAATCCT 
5-HTR4 125 ATGGTGCTGGCCTATTACCG TGAGTGCTATGCTGGTCTGC 
5-HTR6 131 CAGATTCGGACTCAGACGCA GAAGAAATTGACGGCGGCAG 
5-HTR7 149 TGGTGATCTCCGTGTGCTTC TCCAAAGATCCACTTGCCCC 
GAPDH 75 TTGCCCTCAACGACCACTTT CCACCACCCTGTTGCTGTAG 
 840 
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